AU2001294654A1 - Model for neurodegenerative diseases involving amyloid accumulation - Google Patents

Model for neurodegenerative diseases involving amyloid accumulation

Info

Publication number
AU2001294654A1
AU2001294654A1 AU2001294654A AU9465401A AU2001294654A1 AU 2001294654 A1 AU2001294654 A1 AU 2001294654A1 AU 2001294654 A AU2001294654 A AU 2001294654A AU 9465401 A AU9465401 A AU 9465401A AU 2001294654 A1 AU2001294654 A1 AU 2001294654A1
Authority
AU
Australia
Prior art keywords
model
neurodegenerative diseases
diseases involving
amyloid accumulation
involving amyloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001294654A
Inventor
Christine M. Gall
Gary Lynch
Bi Xiaoning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of AU2001294654A1 publication Critical patent/AU2001294654A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
AU2001294654A 2000-09-25 2001-09-25 Model for neurodegenerative diseases involving amyloid accumulation Abandoned AU2001294654A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23537400P 2000-09-25 2000-09-25
US60/235,374 2000-09-25
PCT/US2001/029788 WO2002026107A2 (en) 2000-09-25 2001-09-25 Model for neurodegenerative diseases involving amyloid accumulation

Publications (1)

Publication Number Publication Date
AU2001294654A1 true AU2001294654A1 (en) 2002-04-08

Family

ID=22885234

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001294654A Abandoned AU2001294654A1 (en) 2000-09-25 2001-09-25 Model for neurodegenerative diseases involving amyloid accumulation

Country Status (4)

Country Link
US (2) US7186521B2 (en)
EP (1) EP1326997A4 (en)
AU (1) AU2001294654A1 (en)
WO (1) WO2002026107A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1315971A2 (en) * 2000-07-31 2003-06-04 The Regents of The University of California Model for alzheimer's disease and other neurodegenerative diseases
JP2008539276A (en) * 2005-04-27 2008-11-13 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド Materials and methods for improving the resolution of mutant proteins associated with human disease
KR101397554B1 (en) * 2007-11-09 2014-05-21 재단법인서울대학교산학협력재단 Compositions and method for the diagnosis, prevention and treatment of Alzheimer's disease
ES2368054B1 (en) * 2009-06-16 2012-09-13 Universidad Del Pais Vasco ORGANIC MODEL OF NEURO-DEGENERATIVE DISEASES, PROCESS OF OBTAINING AND USES OF THE SAME
US20160220835A1 (en) * 2013-09-08 2016-08-04 Tylerton International Inc. Apparatus and methods for diagnosis and treatment of patterns of nervous system activity affecting disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) * 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) * 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) * 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US6120991A (en) * 1990-10-30 2000-09-19 Fred Hutchinson Cancer Research Center Epiligrin, an epithelial ligand for integrins
US5830678A (en) * 1990-10-30 1998-11-03 Fred Hutchinson Cancer Research Center Method for identifying a target peptide that modulates the binding of epinectin ligand to integrin receptors
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US5539083A (en) * 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5767337A (en) * 1995-07-31 1998-06-16 Duke University Creation of human apolipoprotein E isoform specific transgenic mice in apolipoprotein deficient "knockout" mice
US6046381A (en) * 1998-04-30 2000-04-04 The Regents Of The University Of California Apolipoprotein E transgenic mice and assay methods
EP1315971A2 (en) * 2000-07-31 2003-06-04 The Regents of The University of California Model for alzheimer's disease and other neurodegenerative diseases

Also Published As

Publication number Publication date
US20080038200A1 (en) 2008-02-14
WO2002026107A2 (en) 2002-04-04
EP1326997A2 (en) 2003-07-16
US7186521B2 (en) 2007-03-06
US20020061515A1 (en) 2002-05-23
EP1326997A4 (en) 2006-01-11
WO2002026107A3 (en) 2002-08-22

Similar Documents

Publication Publication Date Title
EP1555018A4 (en) Remedies for neurodegenerative diseases
WO2002016951A8 (en) Methods for diagnosing a neurodegenerative condition
AU2001278084A1 (en) Model for alzheimer's disease and other neurodegenerative diseases
IL155093A0 (en) Morpholin-acetamide derivatives for the treatment on inflammatory diseases
AU2001286221A1 (en) Remedies for ischemic diseases
EP1449542A4 (en) Genetic remedies for neurodegenerative diseases
AU8622101A (en) Remedies for ischemic diseases
AU2001229592A1 (en) Vaccines against neurodegenerative disorders
AU2001290685A1 (en) Methods for inhibiting inflammatory disease
AU2001257903A1 (en) Method for treatment of neurodegenerative diseases
AU2002214589A1 (en) Protein-protein interactions in neurodegenerative diseases
AU2002221906A1 (en) Method for diagnosing allergic diseases
AU2002213239A1 (en) Protein-protein interactions in neurodegenerative diseases
AU2001241162A1 (en) Remedies for allergic diseases
AU2001294654A1 (en) Model for neurodegenerative diseases involving amyloid accumulation
AUPR544401A0 (en) Animal model for allergy
AU2002315848A1 (en) Remedies for eosinophilic diseases
IL159478A0 (en) Remedies for eosinophilic diseases
AU2001292301A1 (en) Novel drugs for liver diseases
AU5788701A (en) Animal models for neurodegenerative disease
EP1393740A4 (en) Novel remedies for neurodegenerative disease
EP1252895A4 (en) Remedies for ophthalmic diseases
AU2001278533A1 (en) Device for cleaning cast parts
AU2002220822A1 (en) For amyloid formation inhibitors
AU2002218014A1 (en) Apoptosis-inducing ribozymes